DENVER--(BUSINESS WIRE)--Accelr8 Technology Corporation (NYSE Amex: AXK) presented new data at the 109th General Meeting of the American Society for Microbiology (ASM) in Philadelphia. Company scientists and their collaborators from the Washington University in St. Louis School of Medicine (Barnes-Jewish Hospital) reported results for Accelr8’s rapid test for identifying organisms that produce the new “KPC” antibiotic-destroying enzyme. KPC is the first rapidly spreading resistance enzyme to emerge that attacks all members of the largest and most important antibiotic super-family. The family includes a group of drugs known as carbapenems, sometimes called “gorillacillin” by hospital staff because they attack a broad spectrum of otherwise resistant organisms. Because of their importance, physicians prefer to reserve these drugs unless other antibiotics fail.
